Xencor (XNCR) Non-Current Deffered Revenue (2013 - 2024)

Xencor (XNCR) reported Non-Current Deffered Revenue of $94.1 million for Q3 2024, down 9.58% quarter-over-quarter from $104.1 million in Q2 2024.

Xencor (XNCR) Non-Current Deffered Revenue (2013 - 2024) Analysis & Trends

Xencor (XNCR) has 8 years of Non-Current Deffered Revenue data on file, last reported at $94.1 million in Q3 2024.

Non-Current Deffered Revenue for Q3 2024 came in at $94.1 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $94.1 million (changed N/A YoY), and the FY2019 annual result was $1.9 million, up 58.6% from the prior year.
Non-Current Deffered Revenue slipped to $94.1 million in Q3 2024 per XNCR's latest filing, from $104.1 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $104.1 million in Q2 2024 and troughed at $94.1 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Xencor	953.38 Mn	878.64 Mn	-	-

Download Data